Loading clinical trials...

Dydrogesterone-Primed Ovarian Stimulation Protocol Versus Gonadotropin Releasing Hormone Antagonist Protocol in ICSI | Clinical Trials | Clareo Health

UNKNOWNNA

Dydrogesterone-Primed Ovarian Stimulation Protocol Versus Gonadotropin Releasing Hormone Antagonist Protocol in ICSI

Dydrogesterone-Primed Ovarian Stimulation Protocol Versus Gonadotropin Releasing Hormone Antagonist Protocol in Patients With Polycystic Ovary Syndrome Undergoing Intra-Cytoplasmic Sperm Injection

NCT05751681•Zagazig University

View on ClinicalTrials.gov

Summary

GnRH antagonist protocol is currently a good strategy for controlled ovarian stimulation in women with PCOS undergoing IVF/ICSI cycles. Finding a protocol that can be a better alternative will help in improving the success rate of IVF/ICSI cycles

Detailed Description

Progesterone has potent restraint on hypothalamus-pituitary-ovarian axis. It acts on unidentified hypothalamic pulse oscillator neurons. In turn, it acts on gonadotropins releasing hormone (GnRH) secreting neurons leading to inhibition of GnRH secretion. This results in inhibition of both luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from anterior pituitary. The effect of progesterone appears to decrease GnRH pulse frequency which results in slowing down LH pulse frequency and reducing LH plasma concentrations

Eligibility

Age

20 - 40 years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•1. All patients should be candidates for ICSI.
•2. Age between 20-40 years.
•3. Body mass index 18-35 kg/m2.
•4. Diagnosis of PCOS according to modified Rotterdam's criteria

Exclusion Criteria

•1\) Any patient with contraindication to IVF treatment or pregnancy 2) Women with history of intra-uterine abnormality. 3) Severe endometriosis (grade 3 or 4) 4) Clinically significant systemic disease or other endocrinopathy.

Locations (1)

Zagazig University

Zagazig, Egypt

Key Dates

Start Date

February 20, 2023

Primary Completion Date

April 20, 2024

Completion Date

March 20, 2025

Last Updated

March 2, 2023

Enrollment

ESTIMATED participants

Conditions

Ovary CystFertility Issues

Interventions

progestin primed ovarian stimulation protocol

OTHER

dydrogesterone (Duphaston, Abbott)

DRUG

Cetrotide

DRUG

Contacts

mostafa fahmy, mcs

CONTACT

01065644434 mafahmy21@gmail.com

Testicular Tissue Cryopreservation (TTC)

NCT06387498

Fertility Issues

View study

RECRUITINGPHASE2/PHASE3

Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma

NCT05316467

Endometrial CarcinomaObese+2 more

View study

RECRUITINGNA

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 2, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Dydrogesterone-Primed Ovarian Stimulation Protocol Versus Gonadotropin Releasing Hormone Antagonist Protocol in ICSI

Inclusion Criteria

Exclusion Criteria

Testicular Tissue Cryopreservation (TTC)

Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma

UTERINE EVALUATION FOR THE IDENTIFICATION OF PATHOLOGY. This Study Will Compare the Intrauterine Pathology Detection Rate Between Standard of Care Hydrosonography, and a New Visual Saline Infusion Device Providing Direct Visualization of the Uterus.

Determination of Vaginal Colonization and the Effect of an Oral Probiotic (PROSALVAG)

Health Promotion Model, Fertility Awareness, Preconception Knowledge and Attitude

Comparison of Progestin Primed Ovarian Stimulation (PPOS) vs.GnRH Antagonist Methods on IVF Outcomes